Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Alamar Biosciences Q3 2026 Results: Net Loss of $13.3M, Loss Widens

Alamar Biosciences reported total revenue of $89.0 million for the nine months ended September 30, 2026, representing significant growth compared to $49.2 million in the prior year period. Despite this growth, the company incurred a net loss of $47.9 million for the period as it continues to invest heavily in research, development, and commercial expansion.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue33.519.9
Gross profit20.611.9
Profit before tax-13.2-7.6
Net income-13.3-8.0
EPS (diluted, $ a share)$-0.19$-0.69

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+68.5%
Gross margin61.5%
Operating margin-45.1%
Source

10-Q filed with the SEC, NASDAQ: ALMR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Alamar Biosciences, Inc.: key numbers

Share price
$30.55Close, Nov 16
Market cap
$2.12B
Shares outstanding
69.48MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Alamar Biosciences, Inc.

All →
9:02 PM ET Form 4
Insider Selling

Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $2.94M of Stock

Qiming Corporate GP VI Ltd., 10% Owner, sold 100,061 shares of Alamar Biosciences, Inc. at $29.34 to $30.63 a share (average $29.38) in 7 transactions, worth $2.94M in total on Nov 11, 2026. Shares held after the trade: 1,632,188 (-0.0%).

Value
$2.94M
Shares
100,061
Average price
$29.38
Role
10% Owner
Holding change
-0.0%
Trade date
Nov 11, 2026
4:11 PM ET Form 4
Insider Selling

Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $3.33M of Stock

Qiming Corporate GP VI Ltd., 10% Owner, sold 111,313 shares of Alamar Biosciences, Inc. at $29.89 a share, worth $3.33M in total on Nov 3, 2026. Shares held after the trade: 1,650,354 (-1.2%).

Value
$3.33M
Shares
111,313
Average price
$29.89
Role
10% Owner
Holding change
-1.2%
Trade date
Nov 3, 2026
4:16 PM ET Form 4
Insider Selling

Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $5.66M of Stock

Qiming Corporate GP VI Ltd., 10% Owner, sold 187,040 shares of Alamar Biosciences, Inc. at $29.84 to $33.31 a share (average $30.25) in 17 transactions, worth $5.66M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 1,670,586 (-0.5%).

Value
$5.66M
Shares
187,040
Average price
$30.25
Role
10% Owner
Holding change
-0.5%
Trade date
Oct 30, 2026 to Nov 2, 2026
4:11 PM ET 8-K
Financial Results

Alamar Biosciences Financial Results

Alamar Biosciences reported Q3 2026 revenue of $33.5 million, a 68% year-over-year increase driven by strong demand for its NULISA platform and consumables. The company raised its full-year 2026 revenue guidance to a range of $121-$123 million and announced the retirement of President Tod White effective December 31, 2026.

Term
Q3 2026

“Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time. Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.”

Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences

“Tod has been an outstanding partner and leader during a pivotal period for Alamar. He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase. On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement.”

Yuling Luo, Ph.D., Founder, Chief Executive Officer, and Chair of the Company
4:09 PM ET Form 4
Insider Selling

Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $5.96M of Stock

Qiming Corporate GP VI Ltd., 10% Owner, sold 185,597 shares of Alamar Biosciences, Inc. at $30.33 to $33.11 a share (average $32.14) in 19 transactions, worth $5.96M in total between Oct 27, 2026 and Oct 28, 2026. Shares held after the trade: 1,704,596 (-0.5%).

Value
$5.96M
Shares
185,597
Average price
$32.14
Role
10% Owner
Holding change
-0.5%
Trade date
Oct 27, 2026 to Oct 28, 2026
4:11 PM ET Form 4
Insider Selling

Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $8.56M of Stock

Qiming Corporate GP VI Ltd., 10% Owner, sold 280,244 shares of Alamar Biosciences, Inc. at $29.35 to $30.85 a share (average $30.56) in 15 transactions, worth $8.56M in total between Oct 23, 2026 and Oct 26, 2026. Shares held after the trade: 1,738,314 (-1.4%).

Value
$8.56M
Shares
280,244
Average price
$30.56
Role
10% Owner
Holding change
-1.4%
Trade date
Oct 23, 2026 to Oct 26, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.